Major depressive disorder (MDD) is a significant cause of disability worldwide and the most common illness preceding suicide. On March 5, 2019, the nasal spray drug, esketamine, also known as Spravato (by Janssen Pharmaceuticals), was approved by the FDA for treatment-resistant major depression.
...
Esketamine is indicated in combination with an oral antidepressant for the treatment of treatment-resistant depression in adults. It is also indicated for the treatment of depressive symptoms in adults with major depressive disorder experiencing acute suicidal ideation or behaviour.
Peking University First Hospital, Beijing, Beijing, China
the Affiliated Hospital of Yangzhou University, Yangzhou, Jiangsu, China
Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Hunan Provincial Maternal and Child Health Care Hospital, Changsha, Hunan, China
Women's Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Tongji Hospital, Wuhan, Hubei, China
The Second Affiliated Hospital, Chongqing Medical University, Chongqing, Chongqing, China
Maternal and Child Health Hospital of Hubei Province, Wuhan, Hubei, China
Central Arkansas VHS John L. McClellan Memorial Veterans Hospital, Little Rock, AR, Little Rock, Arkansas, United States
New Mexico VA Health Care System, Albuquerque, NM, Albuquerque, New Mexico, United States
Edward Hines Jr. VA Hospital, Hines, IL, Hines, Illinois, United States
Anesthesiology Department, Jinling Hospital Affiliated to Nanjing University, Nanjing, Jiangsu, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.